PD-L1 in small bowel adenocarcinoma is associated with etiology and tumor-infiltrating lymphocytes, in addition to microsatellite instability
- 1 July 2020
- journal article
- research article
- Published by Elsevier BV in Laboratory Investigation
- Vol. 33 (7), 1398-1409
- https://doi.org/10.1038/s41379-020-0497-0
Abstract
No abstract availableKeywords
Funding Information
- San Matteo Hospital Foundation
- MIUR
- Fondazione IRCCS Policlinico San Matteo
This publication has 40 references indexed in Scilit:
- Efficacy and safety of immune checkpoint inhibitors in advanced gastric or gastroesophageal junction cancer: a systematic review and meta-analysisOncoImmunology, 2019
- Small Bowel Carcinomas Associated with Immune-Mediated Intestinal Disorders: The Current KnowledgeCancers, 2018
- The diverse functions of the PD1 inhibitory pathwayNature Reviews Immunology, 2017
- Small bowel carcinomas in celiac or Crohn's disease: distinctive histophenotypic, molecular and histogenetic patternsLaboratory Investigation, 2017
- Could the PD-1 Pathway Be a Potential Target for Treating Small Intestinal Adenocarcinoma?American Journal of Clinical Pathology, 2017
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockadeScience, 2017
- Small Bowel Carcinomas in Coeliac or Crohn’s Disease: Clinico-pathological, Molecular, and Prognostic Features. A Study From the Small Bowel Cancer Italian ConsortiumJournal of Crohn's and Colitis, 2017
- PD-1 Blockade in Tumors with Mismatch-Repair DeficiencyThe New England Journal of Medicine, 2015
- A single-institution experience with 491 cases of small bowel adenocarcinomaThe American Journal of Surgery, 2010
- High-Resolution Array Comparative Genomic Hybridization in Sporadic and Celiac Disease–Related Small Bowel AdenocarcinomasClinical Cancer Research, 2010